Subscribe To
FHTX / Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
FHTX News
By GlobeNewsWire
October 4, 2023
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a ne more_horizontal
By Seeking Alpha
August 16, 2023
Foghorn Therapeutics: Ifs, Buts, And Clinical Holds
Foghorn Therapeutics Inc. stock has increased by 70% in the last 4 months after a clinical hold on their lead program was lifted. Foghorn's technology more_horizontal
By Zacks Investment Research
August 4, 2023
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.70 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compar more_horizontal
By Zacks Investment Research
July 10, 2023
Foghorn Therapeutics Inc. (FHTX) Surges 12.8%: Is This an Indication of Further Gains?
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate r more_horizontal
By Zacks Investment Research
May 8, 2023
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Lags Revenue Estimates
Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compar more_horizontal
By Zacks Investment Research
April 27, 2023
Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock?
Foghorn Therapeutics Inc. (FHTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate r more_horizontal
By Market Watch
April 24, 2023
Foghorn Therapeutics stock slides 21% after FDA puts partial clinical hold on cancer drug trial
Foghorn Therapeutics Inc.'s stock FHTX slid 21% in premarket trade Monday, after the biotech said the Food and Drug Administration has placed a partia more_horizontal
By GlobeNewsWire
April 10, 2023
Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023
CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a n more_horizontal
